On Wednesday, Glenmark Pharmaceuticals said it has launched a triple-fixed-dose combination (FDC) drug for the treatment of diabetes.
Under the name Zita, the compnay has introduced a combination of Teneligliptin, Dapagliflozin and Metformin.
It is indicated to improve glycemic control in patients with Type 2 diabetes.
The company stated that Priced at Rs 14 per tablet (per day), the medication lowers the daily cost of therapy by 30 per cent; making it affordable for the patients.
Currently, the compnay shares are trading 0.75% up at Rs. 807.65.
The drug helps improve glycemic control among adult patients with high HbA1c and other co-morbidities; while also reducing major renal and cardiac adverse events. Glenmark Pharma President & Business Head (India Formulations) Alok Malik said.
According to IQVIA sales data for the 12-month period ending August 2023, the market for oral anti-diabetic drugs in India is estimated at Rs 12,522 crore, with an annual growth of 6.5 per cent against the corresponding period last year.
Glenmark Pharmaceuticals Ltd the company manufactures speciality and generic drugs. Its product category includes novel molecular entities, formulations, and API products.
